Literature DB >> 19305945

Systemic mastocytosis presenting as osteoporosis--a case report.

R Mathew1, V Dhillon, P Shepherd.   

Abstract

Mastocytosis is a clonal disorder of the mast cell and its precursor cells, and is characterised by proliferation and accumulation of mast cells within various organs, most commonly the skin. Systemic mastocytosis is a rare but well-recognised cause of secondary osteoporosis, accounting for about 1.25% of cases. The pathophysiological mechanism is probably multifactorial, including increased osteoclastic activity, and a direct effect of mast cell mediators like histamine, heparin, tryptase and cytokines. Here, we report the case of a middle-aged male patient with osteoporotic vertebral fractures as a rare presenting manifestation of systemic mastocytosis. In summary, systemic mastocytosis, although rare, should be considered as a cause in patients with idiopathic osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19305945     DOI: 10.1007/s10067-009-1165-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  7 in total

1.  H1 and H2 histamine receptors modulate osteoclastic resorption by different pathways: evidence obtained by using receptor antagonists in a rat synchronized resorption model.

Authors:  C Dobigny; J L Saffar
Journal:  J Cell Physiol       Date:  1997-10       Impact factor: 6.384

2.  Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment.

Authors:  A Y N Lim; A J K Ostor; S Love; A J Crisp
Journal:  Ann Rheum Dis       Date:  2005-06       Impact factor: 19.103

3.  [Histological characteristics and prevalence of secondary osteoporosis in systemic mastocytosis. A retrospective analysis of 158 cases].

Authors:  G Delling; H Ritzel; M Werner
Journal:  Pathologe       Date:  2001-03       Impact factor: 1.011

Review 4.  The role of mast cells in osteoporosis.

Authors:  Nicole Chiappetta; Barry Gruber
Journal:  Semin Arthritis Rheum       Date:  2006-07-03       Impact factor: 5.532

Review 5.  Pathogenesis, clinical features, and treatment advances in mastocytosis.

Authors:  A Pardanani; C Akin; P Valent
Journal:  Best Pract Res Clin Haematol       Date:  2006       Impact factor: 3.020

6.  Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B.

Authors:  T Lehmann; C Beyeler; B Lämmle; T Hunziker; P Vock; A J Olah; C Dahinden; N J Gerber
Journal:  Br J Rheumatol       Date:  1996-09

7.  Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.

Authors:  Srdan Verstovsek; Ayalew Tefferi; Jorge Cortes; Susan O'Brien; Guillermo Garcia-Manero; Animesh Pardanani; Cem Akin; Stefan Faderl; Taghi Manshouri; Deborah Thomas; Hagop Kantarjian
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

  7 in total
  2 in total

Review 1.  Rare causes of osteoporosis.

Authors:  Gemma Marcucci; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2015-10-26

Review 2.  The Role of Mast Cells in Bone Metabolism and Bone Disorders.

Authors:  Deniz Ragipoglu; Anne Dudeck; Melanie Haffner-Luntzer; Martin Voss; Jochen Kroner; Anita Ignatius; Verena Fischer
Journal:  Front Immunol       Date:  2020-02-07       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.